Endotoxemia and sepsis are leading causes of mortality in horses and are currently managed primarily with supportive care.

In human and companion animal medicine, extracorporeal hemoperfusion is used to remove circulating toxins and cytokines. In equine medicine, the safety of polymer-based hemoperfusion adsorption columns has recently been established. This study aims to evaluate the safety of a carbon-based hemoperfusion system in adult horses.

We hypothesize that hemoperfusion using an activated carbon column will be well tolerated in healthy horses, with minimal impact on hematologic and hemodynamic parameters.

Six healthy adult horses will undergo hemoperfusion to assess the biocompatibility and safety of the carbon-based adsorption system. Clinical signs, hemodynamic variables, and cytokine levels will be closely monitored throughout the study to define the safety profile of carbon-based hemoperfusion in horses and support future studies targeting endotoxemia treatment.